- Home
- BATL vs ESLA Comparison
BATL vs ESLA Comparison
Compare BATL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$0.72
Company Overview
Basic Information| Metric | BATL | ESLA |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 30.7M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | BATL | ESLA |
|---|---|---|
| Price | $1.41 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.7M | 34.8K |
| Earning Date | 05-13-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.68 |
| 52 Week High | $29.70 | $3.15 |
Technical Indicators
Market Signals| Indicator | BATL | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 36.92 |
| Support Level | $1.09 | $0.70 |
| Resistance Level | $1.87 | $1.35 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.77 | 27.95 |
Price Performance
Historical Comparison BATL
ESLA
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.